Rexahn Pharma completes stage 1 and bgins enrollment in stage 2 Archexin® phase IIa trial
Rexahn Pharma announced that it has identified a maximum tolerated dose and completed Stage 1 of a dose-escalation Phase IIa clinical trial of Archexin in combination with everolimus, a widely used chemotherapy drug, in patients with metastatic renal cell carcinoma. February 08, 2016